EUVIMEDEUVIMED entdecken
Crossref

The value of innovation in breast cancer treatment: real option value of olaparib for first-line treatment of gBRCA-mutated HER2 negative metastatic breast cancer

Cynthia L Gong, Mariana Chavez-MacGregor, Xiaoqing Xu, Leah Park, David Elsea, Sarah Katsandres, Kristen Migliaccio-Walle, David L Veenstra

Breast Cancer Research and Treatment · 2026-06 · 217 (2)

DOI: 10.1007/s10549-026-07988-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 04.06.2026. Verfasst von Cynthia L Gong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Curta Inc., 600 1st Ave, Ste 330, #45802, Seattle, WA, 98104, USA. Cynthia.Gong@curta.com. Hauptthemen laut MEDLINE: Phthalazines, Piperazines, Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Novel drugs for metastatic breast cancer (mBC) can provide patients not only with improved survival but also the opportunity to benefit from future treatment innovations, a concept referred to as real option value (ROV). Quantifying the ROV of first-line (1L) olaparib may help clinicians and patients better understand the additional value increased survival provides through access to future innovative therapies. METHODS: We developed a Markov model with progression-free, progression, and death states to estimate long-term survival gain of 1L olaparib versus treatment of physician's choice (TPC; chemotherapy) among patients with HER2-negative mBC. To derive ROV, a scenario without future drug innovation was compared to one including anticipated innovations as of January 2023. ROV parameters were informed by literature, trial data, ongoing studies, and mBC treatment patterns. Clinician expert-reviewed assumptions generated high-, mid-, and low-ROV scenarios. The primary outcome was aggregated life expectancy, weighted between HR+ and TNBC per OlympiAD trial characteristics. RESULTS: Without innovation, modeled aggregate survival was 3.16 years with olaparib versus 1.81 years with TPC (Δ1.35 LYs). With innovation, survival increased to 3.91 vs. 2.42 LYs in the high scenario (Δ1.49 LYs; +0.139 LYs vs. no innovation), 3.44 vs. 2.02 LYs in the mid-scenario (Δ1.42 LYs; +0.069 LYs), and 3.24 vs. 1.87 LYs in the low-scenario (Δ1.37 LYs; +0.022 LYs), for olaparib vs. TPC respectively. This corresponded to relative survival increases of 10.3%, 5.1%, and 1.6%, respectively. CONCLUSIONS: First-line olaparib directly improves survival and can further extend survival by providing access to future innovations. These findings may guide early treatment selection to optimize sequencing and support further evaluation of ROV for additional guideline-recommended treatments in mBC. KEY OBJECTIVE: Can first-line (1L) olaparib treatment in metastatic breast cancer (mBC) extend survival enough to allow patients to benefit from future treatment innovations, a concept known as real option value (ROV)? KNOWLEDGE GENERATED: A Markov model estimated aggregate survival of 3.16 years with olaparib vs. 1.81 years with chemotherapy among 1L patients with HER2-negative mBC. Incorporating future innovations increased survival with olaparib by an additional 0.022–0.139 years across low-, mid-, and high-ROV scenarios, yielding relative survival gains of 1.6–10.3% compared with no innovation. RELEVANCE: These findings in a modeled patient population indicate that 1L olaparib not only directly improves survival but also enhances patients’ opportunity to access and benefit from future treatments, further extending survival. This type of ROV data may guide clinicians in selecting therapies to optimize sequencing and maximize long-term benefits for patients with mBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesPiperazinesErb-b2 Receptor Tyrosine KinasesBreast NeoplasmsMutationPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsHumansFemaleMarkov ChainsNeoplasm MetastasisTreatment Outcome

Substanzen

olaparibPhthalazinesPiperazinesErb-b2 Receptor Tyrosine KinasesERBB2 protein, humanPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Curta Inc., 600 1st Ave, Ste 330, #45802, Seattle, WA, 98104, USA. Cynthia.Gong@curta.com.
  • University of Texas MD Andersen Cancer Center, Houston, TX, USA.
  • AstraZeneca, Gaithersburg, MD, USA.
  • Curta Inc., 600 1st Ave, Ste 330, #45802, Seattle, WA, 98104, USA.
  • CHOICE Institute, Department of Pharmacy, University of Washington, Seattle, WA, 98195, USA.

Zitieren

APA

Gong, C. L., Chavez-MacGregor, M., Xu, X., Park, L., Elsea, D., Katsandres, S., Migliaccio-Walle, K., & Veenstra, D. L. (2026). The value of innovation in breast cancer treatment: real option value of olaparib for first-line treatment of gBRCA-mutated HER2 negative metastatic breast cancer. Breast Cancer Research and Treatment, 217(2). https://doi.org/10.1007/s10549-026-07988-4

Vancouver

Gong CL, Chavez-MacGregor M, Xu X, Park L, Elsea D, Katsandres S, et al. The value of innovation in breast cancer treatment: real option value of olaparib for first-line treatment of gBRCA-mutated HER2 negative metastatic breast cancer. Breast Cancer Research and Treatment. 2026;217(2). doi:10.1007/s10549-026-07988-4

BibTeX
@article{Gong2026,
  author = {Gong, Cynthia L and Chavez-MacGregor, Mariana and Xu, Xiaoqing and Park, Leah and Elsea, David and Katsandres, Sarah and Migliaccio-Walle, Kristen and Veenstra, David L},
  title = {The value of innovation in breast cancer treatment: real option value of olaparib for first-line treatment of gBRCA-mutated HER2 negative metastatic breast cancer},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  volume = {217},
  number = {2},
  doi = {10.1007/s10549-026-07988-4}
}
Kostenlos starten →